PMID- 17459549
OWN - NLM
STAT- MEDLINE
DCOM- 20070828
LR  - 20220310
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 31
IP  - 5
DP  - 2007 Jun 30
TI  - Treatment with risperidone for 4 weeks increased plasma 
      3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma 
      brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
PG  - 1072-7
AB  - In the present study, we investigated the effects of risperidone treatment for 4 
      weeks on plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and 
      brain-derived neurotrophic factor (BDNF) in 89 schizophrenic patients. We also 
      compared the plasma levels of BDNF and MHPG between the schizophrenic group and 
      103 sex-and age-matched normal controls. In addition, we investigated the effects 
      of two SNPs of the noradrenaline transporter (NAT) gene on plasma levels of MHPG, 
      BDNF, and clinical improvement. The mean dose of risperidone was 3.8+/-1.4 
      mg/day. We demonstrated that treatment with risperidone increased plasma MHPG 
      levels, and this increase was associated with an improvement of the negative 
      symptoms of schizophrenia. In contrast, plasma BDNF did not change after 4 weeks 
      of risperidone treatment, and the two SNPs in NAT did not influence the response 
      to risperidone treatment or plasma MHPG and BDNF levels. These results suggest 
      that the enhancement of noradrenergic neurons by risperidone, which occurs 
      independently of the two SNPs of NAT, plays a role in the clinical efficacy of 
      the drug.
FAU - Yoshimura, Reiji
AU  - Yoshimura R
AD  - Department of Psychiatry, University of Occupational and Environmental Health 
      1-1Iseigaoka, Yahatanishiku, Kitakyushu, Japan. yoshi621@med.uoeh-u.ac.jp
FAU - Hori, Hikaru
AU  - Hori H
FAU - Sugita, Atsuko
AU  - Sugita A
FAU - Ueda, Nobuhisa
AU  - Ueda N
FAU - Kakihara, Shingo
AU  - Kakihara S
FAU - Umene, Wakako
AU  - Umene W
FAU - Nakano, Yuichiro
AU  - Nakano Y
FAU - Shinkai, Koji
AU  - Shinkai K
FAU - Mitoma, Masae
AU  - Mitoma M
FAU - Ohta, Makiko
AU  - Ohta M
FAU - Shinkai, Takahiro
AU  - Shinkai T
FAU - Nakamura, Jun
AU  - Nakamura J
LA  - eng
PT  - Journal Article
DEP - 20070324
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Catecholamines)
RN  - 0 (Isoxazoles)
RN  - 0 (Norepinephrine Plasma Membrane Transport Proteins)
RN  - 0 (Pyrimidines)
RN  - 534-82-7 (Methoxyhydroxyphenylglycol)
RN  - L6UH7ZF8HC (Risperidone)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/blood/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Catecholamines/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Isoxazoles/blood
MH  - Male
MH  - Methoxyhydroxyphenylglycol/*blood
MH  - Middle Aged
MH  - Norepinephrine Plasma Membrane Transport Proteins/blood
MH  - Paliperidone Palmitate
MH  - Polymorphism, Genetic
MH  - Pyrimidines/blood
MH  - Risperidone/blood/*therapeutic use
MH  - Schizophrenia/*blood/*drug therapy
EDAT- 2007/04/27 09:00
MHDA- 2007/08/29 09:00
CRDT- 2007/04/27 09:00
PHST- 2006/12/21 00:00 [received]
PHST- 2007/03/15 00:00 [revised]
PHST- 2007/03/15 00:00 [accepted]
PHST- 2007/04/27 09:00 [pubmed]
PHST- 2007/08/29 09:00 [medline]
PHST- 2007/04/27 09:00 [entrez]
AID - S0278-5846(07)00104-2 [pii]
AID - 10.1016/j.pnpbp.2007.03.010 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1072-7. doi: 
      10.1016/j.pnpbp.2007.03.010. Epub 2007 Mar 24.